Form 4: Maravai LifeSciences General Counsel Sells 25,000 Shares Under 10b5-1 Plan

Kurt Oreshack, General Counsel of Maravai LifeSciences, sold 25,000 shares of Class A Common Stock at $5.03 per share on January 31, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Kurt Oreshack, the General Counsel of Maravai LifeSciences Holdings, Inc., sold 25,000 shares of Class A Common Stock on January 31, 2025.
• The sale was executed at a price of $5.03 per share.
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted by Mr. Oreshack on March 1, 2024.
• Following the sale, Mr. Oreshack directly owns 167,618 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing regarding an insider stock sale under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of trading on inside information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock sales.
• Similar filings are regularly made by executives at other publicly traded companies such as Thermo Fisher Scientific (TMO) and Danaher Corporation (DHR).

Stakeholder Impact

• The stock sale by a company executive may have a minor impact on shareholder sentiment, but the pre-arranged nature of the sale mitigates any significant concerns.

Key Dates

Keywords

Form 4, Maravai LifeSciences, MRVI, insider trading, stock sale, Rule 10b5-1, Kurt Oreshack, General Counsel